Biosynex AAQS 2025

Biosynex AAQS

Ticker

ALBIO.PA

ISIN

FR0011005933

WKN

A1H8G1

Revenue Net Income P/E P/S EBIT Dividend Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE

Biosynex has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Biosynex in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

Biosynex Aktienanalyse

What does Biosynex do?

The company Biosynex SA was founded in 2005 in Strasbourg, France. The company is a manufacturer and distributor of diagnostic test kits used for the rapid and accurate diagnosis of various infectious diseases and other health conditions. Biosynex SA has established itself as a leading player in the global health market in recent years. The business model of Biosynex SA includes the design, manufacture, and distribution of various medical diagnostic tests that are capable of quickly and efficiently detecting pathogens and other health conditions. The company offers a wide range of medical test kits that can be used for the diagnosis of HIV/AIDS, hepatitis C, syphilis, rapid pregnancy tests, menopause, bleeding during pregnancy, vitamin D deficiency, and many other health conditions. The main focus of Biosynex SA is on developing test kits that are easy to use and provide accurate and reliable results. With its technological know-how and collaboration with leading experts in the field of medical diagnostics, Biosynex SA has taken a leading position in the development and marketing of medical diagnostic test kits. By collaborating with doctors, hospitals, and clinics globally, Biosynex SA has successfully expanded its business. Biosynex SA has various business areas specifically focused on the marketing and distribution of medical diagnostic tests. The most well-known areas include gynecology, infectious diseases, and pediatrics. Biosynex SA also has a strong presence in the global market, including Asia, Europe, Africa, and America. One of the most well-known products of Biosynex SA is the HIV self-test called Autotest VIH®, which is available in many European countries and North America. The test kit is CE marked and approved by leading health authorities such as the WHO and the EU. The product is an important tool in reducing the spread of HIV infections and allowing people to make a confidential diagnosis of HIV/AIDS in a private setting. In the field of gynecology, Biosynex SA offers various products such as the Unistick® pregnancy test, Unistick® ovulation test, and Unistick® menopause test kit. These products enable women to easily and efficiently diagnose pregnancy, ovulation, and menopause. The test kits are easy to use, can be used at home, and provide results within minutes. In summary, Biosynex SA has earned its leading position in the global market due to its focus on innovative technology and high-quality product range. The company has made a significant contribution to improving healthcare worldwide with its expertise and commitment to diagnosing health conditions. Biosynex SA will continue to expand its business in the future to support even more people worldwide and further improve the quality of healthcare. Biosynex ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Frequently Asked Questions about Biosynex stock

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Biosynex

Our stock analysis for Biosynex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biosynex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.